PF 06412562 in Subjects With Advanced Stage Parkinson's Disease
Status:
Completed
Trial end date:
2019-04-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of the investigational drug
PF-06412562 compared to the current medical standard of care medication for Parkinson's
disease, carbidopa/levodopa. This research also is being done to find out if the
investigational drug PF-06412562 can help improve the motor (movement) function, alertness,
and cognitive (thinking) skills of people who are considered to be in the advanced-stage of
Parkinson's disease. In this study, PF06412562 is 'investigational,' which means that it is
experimental and has not been approved by the US Food and Drug Administration (FDA), but can
be used in clinical research studies such as this one.
Phase:
Phase 1
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Collaborator:
Pfizer
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa